… tobramycin inhalation solution has been used for over a decade to improve lung function and
reduce exacerbations in patients with cystic fibrosis … use of tobramycin inhaled solution and …

… as an inhaled parenteral solution. Subsequently, a specific tobramycin inhalation solution was
… gold standard efficacy and safety with tobramycin in cystic fibrosis) compared TIP with TIS. …

… Significant microbiologic effect of inhaled tobramycin in young children with cystic fibrosis: a
… treatment effect of inhaled tobramycin in young children with cystic fibrosis. Pediatr Pulmonol…

… binding of tobramycin to mucin in the sputum of cystic fibrosis patients, … It is also important to
note that cystic fibrosis patients are … with respect to tobramycin MIC. One study demonstrated …

Study objectives To determine whether tobramycin solution for inhalation (TSI) can be
administered safely and more efficiently with a new-generation aerosol device, the AeroDose 5.5 …

… Clinical trials of tobramycin inhalation solution (TIS; TOBI®) in patients with cystic fibrosis
(CF) with chronic Pseudomonas aeruginosa infection have shown acute improvement in lung …

… Our objective was to study the effect of tobramycin solution for inhalation (TSI; TOBI®, Chiron
Corp.) on lung function decline rate in 400 young persons with cystic fibrosis (CF) and mild …

… III CF studies of tobramycin inhalation solution (TIS), (TOBI ® ; Novartis, Basel, Switzerland),
the delivery system consisted of 5 mL of a 60 mg/mL tobramycin solution loaded into a LC ® …

… cystic fibrosis and randomly assigned to one of two crossover regimens. Group 1 received
600 mg of aerosolized tobramycin … for 28 days, followed by tobramycin for two 28-day periods. …

… We used the Cystic Fibrosis Foundation registry data to conduct a retrospective cohort study
of the risk of death among cystic fibrosis patients in 1999 according to their use of TSI during …